Form 4: ClearPoint Neuro Director Matthew Klein Receives Equity Grant of 12,417 Restricted Stock Units

ClearPoint Neuro, Inc. Director Matthew B. Klein was granted 12,417 Restricted Stock Units as part of his compensation, aligning his interests with shareholders.

Summary

• Matthew B. Klein, a Director of ClearPoint Neuro, Inc. (CLPT), acquired 12,417 Restricted Stock Units (RSUs).
• The transaction occurred on May 22, 2025.
• Each RSU represents a contingent right to receive one share of ClearPoint Neuro, Inc. common stock.
• The RSUs were acquired at a price of $0, which is typical for equity compensation grants.
• Following this transaction, Matthew B. Klein directly beneficially owns 12,417 derivative securities (Restricted Stock Units).
• The RSUs are scheduled to vest on the earlier of May 22, 2026 (the first anniversary of the grant date) or the day immediately preceding the Company's 2026 annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The grant of equity compensation to a director is a routine and generally positive event as it aligns interests, but it does not indicate significant operational or financial news.

Positives

• The grant of Restricted Stock Units to Director Matthew B. Klein aligns his financial interests with those of the company's shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice for retaining and motivating key personnel and directors.

Future Outlook

The Restricted Stock Units granted to Director Matthew B. Klein are scheduled to vest on the earlier of May 22, 2026, or the day immediately preceding the Company's 2026 annual meeting of stockholders, indicating a future equity distribution.

Industry Context

This filing represents a routine equity compensation grant to a director, a common practice across industries to align the interests of board members with long-term shareholder value creation. Such grants are a standard component of executive and director compensation packages in publicly traded companies, particularly in the medical device and neuro-navigation sectors where ClearPoint Neuro operates.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially fostering long-term value creation.
• Director (Matthew B. Klein): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• Vesting of the 12,417 Restricted Stock Units on the earlier of May 22, 2026, or the day preceding the Company's 2026 annual meeting of stockholders.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Form 4, Restricted Stock Units, RSU, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership